460 results on '"Barritt, A. Sidney"'
Search Results
2. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
3. A Yellow Flower With Jaundice Power: Liver Injury Attributed to Greater Celandine
4. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study
5. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
6. Liver Injury Associated with Turmeric—A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]
7. Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort
8. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
9. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
10. Nutrition as Therapy in Liver Disease
11. Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends
12. SAT-212 Real-world use of Glucagon-like peptide 1 receptor agonists in patients with MASLD: a cross-sectional analysis from TARGETNASH
13. SAT-476 Development of a preference elicitation tool for treatment choice in unresectable, early/intermediate stage HCC
14. Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices
15. SARS-CoV-2 infection in patients with autoimmune hepatitis
16. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions
17. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
18. HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition
19. Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype
20. Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
21. Roux-en-Y Gastric Bypass Is Associated With Increased Hazard for De Novo Alcohol-related Complications and Liver Disease
22. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection
23. Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study
24. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
25. S1541 Statewide Survey of Primary Care, Gastroenterology, and Hepatology Providers on Hepatocellular Carcinoma Risk Stratification and Surveillance Practices
26. S3482 A Yellow Flower With Jaundice Power: A Case of Severe Liver Injury Attributed to Greater Celandine
27. Unique Challenges of Hepatitis C in Infants, Children, and Adolescents
28. Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse
29. Supplementary Table 6 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
30. Supplementary Table 11 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
31. Data from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
32. Supplementary Table 9 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
33. Supplementary Table 2 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
34. Supplementary Table 4 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
35. Supplementary Table 7 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
36. Supplementary Methods from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
37. Supplementary Table 3 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
38. Supplementary Table 8 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
39. Supplementary Table 5 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
40. Hepatocellular Carcinoma Surveillance Among Individuals with Cirrhosis: Trends by Payer, Etiology and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010-2018
41. Liver transplantation from a SARS-COV-2-positive donor: A road ahead or not
42. NAFLD and liver transplantation: Current burden and expected challenges
43. Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis
44. Intestinal microbiota in liver disease
45. Decreasing Mortality Among Patients Hospitalized With Cirrhosis in the United States From 2002 Through 2010
46. Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype
47. SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes
48. Tangible Resources for Multidisciplinary Treatment of Patients With Nonalcoholic Fatty Liver Disease
49. S1313 Diagnostic Performance of FIB-4, APRI, and NFS to Estimate Liver Fibrosis in Hepatic Sarcoidosis
50. A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.